Weekly Top News – Psoriasis – June 29, 2020

June 29, 2020

bimekizumab (UCB4940) / UCB; Stelara (ustekinumab) / J&J
First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis (Canada Newswire) – Jun 22, 2020 – P3, N=435; BE READY (NCT03410992); P3, N=570; BE VIVID (NCT03370133); Sponsor: UCB Biopharma S.P.R.L.; “UCB Canada Inc., today shared the first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting held on June 12, 2020. Patients treated with bimekizumab achieved superior skin clearance in both the BE VIVID and BE READY Phase 3 studies, compared to those who received placebo or Stelara (ustekinumab)….The two late-breaking presentations cited in this release are…Kim A. Papp, Andrew Blauvelt, Richard Langley…Kenneth Gordon…Mark Lebwohl.”


Skilarence (dimethyl fumarate) / Almirall; Fumaderm (dimethyl fumarate) / Biogen
To evaluate the long-term efficacy and tolerability of treatment with dimethyl fumarate in adults with chronic plaque psoriasis. Valutare l’efficacia e la tollerabilità a lungo termine del trattamento con dimetilfumarato in adulti affetti da psoriasi cronica a placche . (clinicaltrialsregister.eu) – Jun 25, 2020 – P3; N=300; Ongoing; Sponsor: ALMIRALL SPA


Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Israel approves new psoriasis treatment (The Jerusalem Post) – Jun 25, 2020 – “Skyrizi – A new treatment for psoriasis that has been recently approved is now being available to treat Israeli psoriasis patients and it has demonstrated therapeutic success, even in severe cases.”


BMS-986165 / BMS
BMS-986165: Data from P2 trial (NCT03881059) for psoriatic arthritis in H2 2020 (Bristol-Myers Squibb) – Jun 27, 2020 – Investor Series Immunology and Cardiovascular: Data from P2 trial (NCT03252587) for systemic lupus erythematosus in 2021



Novartis Cosentyx gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile (Novartis Press Release) – Jun 26, 2020 – “Novartis…today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to


bimekizumab (UCB4940) / UCB
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) (clinicaltrials.gov) – Jun 23, 2020 – P3; N=38; Active, not recruiting; Sponsor: UCB Biopharma S.P.R.L.; N=255 –> 38

No Comments

Post a Comment